Nachrichten aus der Brüder-Gemeine, 1834, no. 04

The Moravian Church's monthly journal of its worldwide activities, including in Labrador, published from 1819-94

MOESM1 of SP, CGRP changes in pyridoxine induced neuropathic dogs with nerve growth factor gene therapy

Additional file 1: Figure S1. Nerve growth factor (NGF) immunostaining of the dorsal root ganglion (DRG) in the vehicle-treated (A), and NGF gene-treated (B) groups at 4 weeks after 1 week of pyridoxine injection. In the vehicle-treated group, NGF immunoreactive neurons are not detectable in the DRG. In the NGF gene-treated group, NGF immunoreactive neurons are abundantly observed in the DRG. Scale bar = 50 μm

Additional file 1: Figure S1. of Sac-1004, a vascular leakage blocker, reduces cerebral ischemia—reperfusion injury by suppressing blood–brain barrier disruption and inflammation

Sac-1004 increases HBMEC survival. HBMECs were starved and treated with various concentrations of Sac-1004. Chemical structure of Sac-1004 (A). Cell survival was detected using an MTT assay (B). Under the same experimental conditions, cell viability was also determined by microscopy after incubation for 48 h (C). All data are presented the means ± SEM. ***P < 0.001. (JPG 82 kb

Additional file 1: Table S1. of Efficient strategy for the molecular diagnosis of intractable early-onset epilepsy using targeted gene sequencing

List of 172 targeted genes included in the epilepsy panel. Table S2. Clinical and demographic information of the patients. Table S3. Quality control matrices of NGS test results for all patients in this study. Table S4. Diagnostic yield of targeted NGS according to types of epilepsy syndrome. Table S5. Clinical factors associated with genetic abnormalities. (XLSX 31 kb